Obeticholic acid
Таблетки, покрытые пленочной оболочкойSelective agonist of the farnesoid X receptor (FXR), nuclear receptors located in the liver and intestine
Indications
For the treatment of primary biliary cholangitis (PBC) in persons over 18 years of age: in combination with ursodeoxycholic acid (UDCA) - in patients with insufficient therapeutic response to UDCA administration; as monotherapy - in patients with UDCA intolerance.
Contraindications
Hypersensitivity to obeticholic acid; decompensated liver cirrhosis (e.g. Child-Pugh class B or C), including history; complete biliary tract obstruction.
Usage
Taken orally.
In patients taking bile acid-binding resins, obeticholic acid should be taken at the maximum possible interval - at least 4-6 h before or 4-6 h after taking the resin.
Before starting treatment with obeticholic acid, the patient's liver status should be assessed. The presence of decompensated liver cirrhosis (Child-Pugh class B or C) or decompensation in the patient's history should be excluded before treatment, as obeticholic acid is contraindicated in these patients.
The starting dose of obeticholic acid is 5 mg once/d for the first 6 months. After the first 6 months, in patients in whom adequate reduction of alkaline phosphate and/or total bilirubin levels is not achieved and who tolerate therapy well, the dose of obeticholic acid is increased to the maximum - 10 mg once/day.
Have questions? Contact Us
Has contraindications. Needs specialist overview.